{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:51:53Z","timestamp":1789685513229,"version":"4.0.1"},"reference-count":52,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"unspecified","delay-in-days":55,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,7,29]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the efficacy of long-term treatment with risankizumab across the updated Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) domains and key related conditions of psoriatic arthritis (PsA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This post hoc analysis primarily used data from the phase 3 KEEPsAKE 1 trial of adult patients with PsA, with data from KEEPsAKE 2 pooled for prespecified outcomes. Outcomes measuring risankizumab efficacy across key GRAPPA-recognised domains of PsA (peripheral arthritis, enthesitis, dactylitis, skin and nail psoriasis, axial disease) and PsA-related conditions such as inflammatory bowel disease (IBD) and uveitis were assessed over 100 weeks of treatment (~2 years). Statistical approaches included non-responder imputation (as-observed with imputation) for categorical variables and mixed-effect model for repeated measures for continuous variables including as-observed measurements at all visits. PsA-related conditions were evaluated via adverse events through 100 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, in KEEPsAKE 1 and KEEPsAKE 2, 412\/483 (85.3%) and 181\/224 (80.8%) of patients randomised to risankizumab completed treatment to week 100. Risankizumab demonstrated efficacy across all GRAPPA-defined domains through 100 weeks, including swollen and tender joint counts, enthesitis, dactylitis, skin and nail outcomes, and axial disease. In KEEPsAKE 1, 42.4% of patients had achieved a Disease Activity in Psoriatic Arthritis measurement of low disease activity and 62.9% had reached a minimal clinically important difference in pain at week 100. Rates of new onset or flare of IBD and uveitis were low.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Treatment with risankizumab provides durable improvement in the signs and symptoms of PsA across all GRAPPA disease domains and related conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-005522","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T02:10:14Z","timestamp":1756174214000},"page":"e005522","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct03675308","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03671148","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C","family":"Coates","sequence":"first","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2344-2285","authenticated-orcid":false,"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital Universitario Marqu\u00e9s de Valdecilla, IDIVAL, Santander, Spain"},{"name":"Department of Rheumatology, Hospital Universitario Marqu\u00e9s de Valdecilla, IDIVAL, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8750-7186","authenticated-orcid":false,"given":"Frank","family":"Behrens","sequence":"additional","affiliation":[{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany"},{"name":"Department of Rheumatology, Goethe University Frankfurt, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[{"name":"University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Van den Bosch","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ranza","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Unit, Hospital das Cl\u00ednicas, Federal University of Uberl\u00e2ndia, Uberl\u00e2ndia, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Klionsky","sequence":"additional","affiliation":[{"name":"Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M","family":"Soliman","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chen","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Coombs","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyu","family":"Shi","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie R","family":"Urbanik","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Iyile","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Lippe","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4528-310X","authenticated-orcid":false,"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[{"name":"INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, INSERM, Sorbonne Universite, Paris, France"},{"name":"APHP, Department of Rheumatology, Hopital Universitaire Pitie Salpetriere, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"2025082519100610000_11.3.e005522.1","doi-asserted-by":"crossref","DOI":"10.1186\/s12955-020-01422-z","article-title":"Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire","volume":"18","author":"Coates","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"2025082519100610000_11.3.e005522.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2025082519100610000_11.3.e005522.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"2025082519100610000_11.3.e005522.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.07.001"},{"key":"2025082519100610000_11.3.e005522.5","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-013-0032-x"},{"key":"2025082519100610000_11.3.e005522.6","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1833"},{"key":"2025082519100610000_11.3.e005522.7","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64 Suppl 2","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2025082519100610000_11.3.e005522.8","doi-asserted-by":"crossref","DOI":"10.5041\/RMMJ.10279","article-title":"Comorbidities in Patients with Psoriatic Arthritis","volume":"8","author":"Haddad","year":"2017","journal-title":"Rambam Maimonides Med J"},{"key":"2025082519100610000_11.3.e005522.9","first-page":"1417","article-title":"Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines","volume":"33","author":"Kavanaugh","year":"2006","journal-title":"J Rheumatol"},{"key":"2025082519100610000_11.3.e005522.10","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025082519100610000_11.3.e005522.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210242"},{"key":"2025082519100610000_11.3.e005522.12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2023.105534","article-title":"Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: Findings from a real-world study in the United States and Europe","volume":"90","author":"Walsh","year":"2023","journal-title":"Joint Bone Spine"},{"key":"2025082519100610000_11.3.e005522.13","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1032491"},{"key":"2025082519100610000_11.3.e005522.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225531"},{"key":"2025082519100610000_11.3.e005522.15","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/rheumatology\/keac607","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study","volume":"62","author":"Kristensen","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025082519100610000_11.3.e005522.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221019"},{"key":"2025082519100610000_11.3.e005522.17","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1111\/jdv.18475","article-title":"The effect of risankizumab on achieving minimal clinically important differences in patient-reported outcomes in patients with psoriatic arthritis: results from KEEPsAKE 1 and 2","volume":"36","author":"Kristensen","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082519100610000_11.3.e005522.18","first-page":"e389","article-title":"Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis: results from KEEPsAKE 1","volume":"36","author":"Kristensen","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082519100610000_11.3.e005522.19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/rheumatology\/keac342","article-title":"Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1","volume":"62","author":"Kristensen","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025082519100610000_11.3.e005522.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221048"},{"key":"2025082519100610000_11.3.e005522.21","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/rheumatology\/keac605","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study","volume":"62","author":"\u00d6st\u00f6r","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025082519100610000_11.3.e005522.22","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002286","article-title":"Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2","volume":"8","author":"Ostor","year":"2022","journal-title":"RMD Open"},{"key":"2025082519100610000_11.3.e005522.23","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110392"},{"key":"2025082519100610000_11.3.e005522.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.23568"},{"key":"2025082519100610000_11.3.e005522.25","first-page":"1745","article-title":"Development of an assessment tool for dactylitis in patients with psoriatic arthritis","volume":"32","author":"Helliwell","year":"2005","journal-title":"J Rheumatol"},{"key":"2025082519100610000_11.3.e005522.26","first-page":"123","article-title":"The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis","volume":"34","author":"Cassell","year":"2007","journal-title":"J Rheumatol"},{"key":"2025082519100610000_11.3.e005522.27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2016.03.519","article-title":"Evaluation of a Novel Clinician Reported Outcome in Nail Psoriasis","volume":"19","author":"Hudgens","year":"2016","journal-title":"Value Health"},{"key":"2025082519100610000_11.3.e005522.28","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1111\/jdv.17387","article-title":"Development and validation of the Physician\u2019s Global Assessment of Fingernail Psoriasis","volume":"35","author":"Hudgens","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082519100610000_11.3.e005522.29","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025082519100610000_11.3.e005522.30","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20575"},{"key":"2025082519100610000_11.3.e005522.31","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40744-024-00654-5","article-title":"Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial","volume":"11","author":"Kristensen","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2025082519100610000_11.3.e005522.32","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s40744-024-00657-2","article-title":"Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial","volume":"11","author":"\u00d6st\u00f6r","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2025082519100610000_11.3.e005522.33","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200371"},{"key":"2025082519100610000_11.3.e005522.34","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.129726"},{"key":"2025082519100610000_11.3.e005522.35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213328"},{"key":"2025082519100610000_11.3.e005522.36","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025082519100610000_11.3.e005522.37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/art.40759","article-title":"Ustekinumab Fails to Show Efficacy in a Phase III Axial Spondyloarthritis Program: The Importance of Negative Results","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025082519100610000_11.3.e005522.38","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2025082519100610000_11.3.e005522.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31713-6"},{"key":"2025082519100610000_11.3.e005522.40","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jaad.2023.07.1024","article-title":"Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up","volume":"89","author":"Papp","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2025082519100610000_11.3.e005522.41","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/bjd.20595","article-title":"Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up","volume":"185","author":"Papp","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025082519100610000_11.3.e005522.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30952-3"},{"key":"2025082519100610000_11.3.e005522.43","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/jdv.19748","article-title":"Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256\u2009weeks (LIMMitless trial)","volume":"38","author":"Strober","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082519100610000_11.3.e005522.44","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19341"},{"key":"2025082519100610000_11.3.e005522.45","first-page":"9","article-title":"Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study","volume":"19","year":"2023","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2025082519100610000_11.3.e005522.46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00467-6"},{"key":"2025082519100610000_11.3.e005522.47","doi-asserted-by":"crossref","unstructured":"Peyrin-Biroulet L , Chapman C , Colombel J-F , et al . S1 Risankizumab Versus Ustekinumab in Patients With Moderate to Severe Crohn\u2019s Disease: Results From the Phase 3B SEQUENCE Trial. Official J Am College Gastroenterol 2023;12S.","DOI":"10.14309\/01.ajg.0000995740.88073.c5"},{"key":"2025082519100610000_11.3.e005522.48","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002781"},{"key":"2025082519100610000_11.3.e005522.49","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ard.2025.06.133","article-title":"POS0773 Low Uveitis Rates In Patients With Axial Spondyloarthritis Or Psoriatic Arthritis Treated With Bimekizumab: Long-Term Results From Phase 2b\/3 Trials","volume":"84","author":"van der Horst-Bruinsma","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2025082519100610000_11.3.e005522.50","doi-asserted-by":"crossref","unstructured":"Mease PP , Bajracharya R , Ink B , et al . Updated Long-Term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Pooled Results from Phase 2b\/3 Studies. Arthritis Rheumatol 2024;76.","DOI":"10.1093\/rheumatology\/keaf142.214"},{"key":"2025082519100610000_11.3.e005522.51","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/annrheumdis-2023-eular.2394","article-title":"OP0061 Development of extra-musculoskeletal manifestations in upadacitinib-treated patients with psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis","volume":"82","author":"Poddubnyy","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025082519100610000_11.3.e005522.52","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.4806"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-005522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T02:10:21Z","timestamp":1756174221000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-005522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,8,25]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/rmdopen-2025-005522"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-005522","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}